J Korean Neurosurg Soc.  2018 May;61(3):402-406. 10.3340/jkns.2018.0044.

Malignant Brain Tumours in Children : Present and Future Perspectives

• Rutka JT

• KMID: 2417365
• DOI: http://doi.org/10.3340/jkns.2018.0044

Abstract

In contrast to many of the malignant tumors that occur in the central nervous system in adults, the management, responses to therapy, and future perspectives of children with malignant lesions of the brain hold considerable promise. Within the past 5 years, remarkable progress has been made with our understanding of the basic biology of the molecular genetics of several pediatric malignant brain tumors including medulloblastoma, ependymoma, atypical teratoid rhabdoid tumour, and high grade glioma/diffuse intrinsic pontine glioma. The recent literature in pediatric neuro-oncology was reviewed, and a summary of the major findings are presented. Meaningful sub-classifications of these tumors have arisen, placing children into discrete categories of disease with requirements for targeted therapy. While the mainstay of therapy these past 30 years has been a combination of central nervous system irradiation and conventional chemotherapy, now with the advent of high resolution genetic mapping, targeted therapies have emerged, and less emphasis is being placed on craniospinal irradiation. In this article, the present and future perspective of pediatric brain malignancy are reviewed in detail. The progress that has been made offers significant hope for the future for patients with these tumours.

Keyword

Medulloblastoma; Ependymoma; Diffuse intrinsic pontine glioma; Atypical teratoid rhabdoid tumour; Molecular genetics; Classification

MeSH Terms

Adult
Biology
Brain Neoplasms
Brain*
Central Nervous System
Child*
Classification
Craniospinal Irradiation
Drug Therapy
Ependymoma
Glioma
Hope
Humans
Medulloblastoma
Molecular Biology

Reference

References

1. Alli S, Figueiredo CA, Golbourn B, Sabha N, Yijun M, Bondoc A, et al. Brainstem blood brain barrier disruption using focused ultrasound. J Control Release. 2018; under revision.

2. Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 59:74–79. 1999.

3. Biggs PU, Garen PD, Powers JM, Garvin AJ. Malignant rhabdoid tumor of the central nervous system. Hum Pathol. 18:332–327. 1987.

4. Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 31. 737–754.e6. 2017.

5. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 7:813–820. 2006.

6. Gómez S, Garrido-Garcia A, Garcia-Gerique L, Lemos I, Suñol M, de Torres C, et al. A novel method for rapid molecular subgrouping of medulloblastoma. Clin Cancer Res. 24:1355–1363. 2018.

7. Guerreiro Stucklin AS, Ramaswamy V, Daniels C, Taylor MD. Review of molecular classication and treatment implications of pediatric brain tumors. Curr Opin Pediatr. 30:3–9. 2018.

8. Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D, et al. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol. 129:669–678. 2015.

9. Mack SC, Pajtler KW, Chavez L, Okonechnikov K, Bertrand KC, Wang X, et al. Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature. 553:101–105. 2018.

10. Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stütz AM, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature. 506:445–450. 2014.

11. Morrissy AS, Cavalli FMG, Remke M, Ramaswamy V, Shih DJH, Holgado BL, et al. Spatial heterogeneity in medulloblastoma. Nat Genet. 49:780–788. 2017.

12. Muller M, Hubbard SL, Provias J, Greenberg M, Becker LE, Rutka JT. Malignant rhabdoid tumour of the pineal region. Can J Neurol Sci. 21:273–277. 1994.

13. Northcott PA, Buchhalter I, Morrissy AS, Hovestadt V, Weischenfeldt J, Ehrenberger T, et al. The whole-genome landscape of medulloblastoma subtypes. Nature. 547:311–317. 2017.

14. Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, et al. Subgroup specific structural variation across 1,000 medulloblastoma genomes. Nature. 488:49–56. 2012.

15. Patterson E, Farr RF. Cerebellar medulloblastoma: treated by irradiation of the whole central nervous system. Acta Radiol. 39:323–336. 1953.

16. Sturm D, Bender S, Jones DT, Lichter P, Grill J, Becher O, et al. Pediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer. 14:92–107. 2014.

17. Torchia J, Golbourn B, Feng S, Ho KC, Sin-Chan P, Vasiljevic A, et al. Integrated (epi)-Genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors. Cancer Cell. 30:891–908. 2016.

18. Torchia J, Picard D, Lafay-Cousin L, Hawkins CE, Kim SK, Letourneau L, et al. Molecular subgroups of atypical teratoid rhabdoid tumors in children: an integrated genomic and clinicopathological analysis. Lancet Oncol. 16:569–582. 2015.

19. Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell. 20:143–157. 2011.

20. Zhou Z, Singh R, Souweidane MM. Convection-enhanced delivery for diffuse intrinsic pontine glioma treatment. Curr Neuropharmacol. 15:116–128. 2017.